In addition, lung cancer cell lines harboring PIK3CA or PTEN mutations were sensitive to dual PIK3CA/mTOR inhibitors [28, 29], which raises the hope that patients with mutations in the PI3K pathway may benefit from this type of targeted therapy in the future. This evidence concerns the gene PIK3CA and lung cancer.